QSV Biologics, Ltd. and, Alseres Pharmaceuticals, Inc., Sign Contract for cGMP Manufacture of Cethrin(R) for Spinal Cord Injury

EDMONTON, July 10 /CNW/ -

QSV Biologics, Ltd (QSV), a North American based biologics CMO located in Edmonton, Canada, and Alseres Pharmaceuticals, Inc., (Alseres) a publicly traded (Nasdaq: ALSE) Central Nervous System diagnosis and treatment company located in Hopkinton, Massachusetts, U.S.A., announced today the signing of a contract for the process development and cGMP manufacturing of Cethrin(R) for spinal cord injury. QSV will be responsible for technology transfer, process development and cGMP manufacture of phase IIb/III clinical trial material in their commercially licensed cGMP manufacturing facility. Cethrin(R), licensed by Alseres from BioAxone Therapeutics, is a Rho inhibitor that stimulates axon regeneration.

Graeme Macaloney PhD, PEng, QSV President & CEO said: "This first-in-field therapy for acute spinal cord injury is an exciting breakthrough, given that there are no approved alternatives. We are proud to be providing the manufacture of this important spinal cord therapeutic for Alseres, which has received Orphan Drug designation from the US-FDA".

"We are pleased to commence our relationship with QSV Biologics for the cGMP manufacturing of Cethrin," commented Mark Pykett, President and COO of Alseres. "As Alseres prepares to initiate its Phase IIb/III clinical trials in acute spinal cord injury later this year, we believe that QSV provides technical know-how and value to this program-critical process."

Alseres Pharmaceuticals, Inc. (ALSE), previously Boston Life Sciences, is engaged in the clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. Cethrin(R), a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, has reported positive interim results in a Phase I/IIa clinical trial. ALTROPANE(R) molecular imaging agent is in Phase III clinical trials for the diagnosis of Parkinson's Disease (PD). The company's research and pre-clinical CNS programs include Inosine for the treatment of spinal cord injury and stroke, a DAT blocker for the treatment of Parkinson's disease, and a second generation technetium-based molecular imaging agent for PD and ADHD. Alseres' current research collaborations include Harvard Medical School and Children's Hospital Boston.

QSV Biologics, Ltd. (, is an international cGMP biologics contract manufacturer (CMO) providing microbial fermentation & cell culture, and purification services. QSV's facility has an 11 yr track-record including an Establishment License suitable for manufacturing clinical trial and commercial biologics. QSV was the sole recipient of the prestigious international Frost & Sullivan "Customer Value Enhancement Award" in 2005. QSV's clientele span three continents and develop protein therapeutics, vaccines & diagnostics. As a dedicated CMO with no competing products of its own, QSV builds value for its clients by producing quality products in a timely manner. Hence its acronym: QSV: Quality & Speed build Value.

For further information: Richard Hetrick, M.Sc., B.Sc., Director of
Business Development, QSV Biologics, Ltd., Ph: (780) 438-5722 Ext. 1,
Email:; Sharon Correia, Director, Corporate Communications, Alseres Pharmaceuticals, Inc., Ph: (508) 497-2360 ext. 224, Email: